REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/08/2025
Voltar para busca
Dado oficial do USPTO
LEUKOTAC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
LEUKOTAC
ST13
US500000087849391Classe
5, 42, 44
Pedido
87849391
Registro
6115761
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
05/08/2025
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
26/03/2018
Data de registro
04/08/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/08/2020
Última transação
05/08/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
MILAN, IT
Examinador
GARTNER, JOHN
Unidade examinadora
L20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
MEDIOLANUM FARMACEUTICI S.P.A.
E. B. (pessoa física)
Representantes
Michelle P. Ciotola CANTOR COLBURN LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for immuno-oncology and autoimmune disease; pharmaceutical preparationsimmunotherapy monoclonal antibodies for immuno-oncology and for the treatment of autoimmune diseases; veterinary preparations for immuno-oncology and autoimmune disease; veterinary preparationsimmunotherapy monoclonal antibodies for immuno-oncology and for the treatment of autoimmune diseases; biotechnological preparations for medical and veterinary useimmunotherapy monoclonal antibodies for immuno-oncology and for the treatment of autoimmune diseases
Classe 42
Research and consultancy in the field of biotechnology; research and development in the field of biotechnology; scientific and technical consultationengineering evaluations and appraisals in the fields of science and technology; scientific and technology research in the field of immuno-oncology and autoimmune disease; laboratory research and analysis services in the field of immuno-oncology and autoimmune disease; scientific chemistrybiology and biotechnology laboratories; scientific laboratory services; laboratory testingresearch and development of new products for others; conducting clinical trials for others in the field of medicinesmolecules and medical devices; medical laboratory analysis services relating to the treatment of persons; medical laboratory servicesincluding sample analysis; medical laboratory analysis services
Classe 44
Medical services; pharmaceutical advice
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
24/01/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/08/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/05/2020
PUBO
PUBLISHED FOR OPPOSITION
19/05/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/04/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/04/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/04/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/04/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/04/2020
GNFR
FINAL REFUSAL E-MAILED
03/04/2020
CNFR
FINAL REFUSAL WRITTEN
03/04/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/02/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
26/02/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
24/02/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
24/02/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
24/02/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/02/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/02/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
24/02/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
28/08/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
28/08/2019
CNSI
SUSPENSION INQUIRY WRITTEN
28/08/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
28/02/2019
GNSL
LETTER OF SUSPENSION E-MAILED
28/02/2019
CNSL
SUSPENSION LETTER WRITTEN
28/02/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/01/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/01/2019
ALIE
ASSIGNED TO LIE
17/01/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/01/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/07/2018
GNRT
NON-FINAL ACTION E-MAILED
12/07/2018
CNRT
NON-FINAL ACTION WRITTEN
12/07/2018
DOCK
ASSIGNED TO EXAMINER
11/07/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/04/2018
NWAP
NEW APPLICATION ENTERED
29/03/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LEUKOTAC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.